Lead Product(s) : Galicaftor,Navocaftor
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Sionna Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Sionna Expands CF Pipeline with AbbVie License Agreement
Details : Under the terms of the agreement, Sionna will assume all development for ABBV-2222 (galicaftor), which is being evaluated in combination with navocaftor for the treatment of Cystic Fibrosis.
Product Name : ABBV-2222
Product Type : Small molecule
Upfront Cash : Undisclosed
July 16, 2024
Lead Product(s) : Galicaftor,Navocaftor
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Sionna Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?